Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company ...

This is Buc-ee’s El Paso County’s statement that no Buc-ee’s application has been filed misses the point entirely. What is ...

Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio ...

Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

24/7 Market News encourages readers and industry observers to obtain a copy of this month’s National Geographic to review the ...

Gilead Sciences to buy biotechnology company, Arcellx for up to $7.8 billion: Foster City, California Wednesday, February 25, 2026, 14:00 Hrs [IST] Gilead Sciences, Inc., a biopha ...

Gilead Sciences agreed to acquire Arcellx in a deal valued at approximately $7.8 billion in total, deepening its push into cell therapy for multiple myeloma.

There's also skepticism from London’s famed black cab drivers, who must pass a grueling training course known as “The Knowledge,” which requires memorizing hundreds of routes and takes years to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value ...

Gilead Sciences ( GILD) has agreed to acquire biotechnology company Arcellx ( ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an ...